Improvements in the therapeutics landscape of the hepatorenal syndrome treatment market are creating new avenues in incremental opportunities for healthcare companies. Although surgical treatments dominate the hepatorenal syndrome (HRS) treatment market, analysts at Transparency Market Research (TMR) anticipate an exponential growth for therapeutics in terms of market value share. Therapeutics are projected to rise from a market value share of ~1% in 2018 to ~6% by the end of 2027, in the hepatorenal syndrome treatment market. Thus, lucrative opportunities in the therapeutics landscape are attracting the attention of healthcare companies.
Healthcare companies are developing improved formulations of therapeutic drugs that are safe and effective for HRS patients. For instance, in May 2019, Mallinckrodt - a global specialty pharmaceutical company, announced the launch of Terlipressin - an investigational agent for the treatment of type 1 hepatorenal syndrome.
Since there are no treatments approved in the U.S. and Canada for HRS-1, healthcare companies are increasing their research efforts to reach full potential in terms of the enrollment of participants. Thus, active enrollment of participants in clinical studies will help enhance the credibility of research outcomes in the hepatorenal syndrome treatment market.
Complications of cirrhosis lead to HRS and progressive kidney failure amongst patients with severe liver damage. Hence, healthcare providers prescribe albumin to cirrhotic patients with acute decompensation. Albumin is gaining increased popularity in the hepatorenal syndrome treatment market, since it serves as a cost-effective treatment option for HRS and cirrhosis. As such, there is growing demand for albumin in hospitals and ambulatory surgical centers across Germany, Italy, and Spain.
Healthcare companies in the hepatorenal syndrome treatment market are increasing their production capabilities of albumin, since the protein serves as a low-cost and effective alternative to saline, gelatin, and no fluid treatment of large volume paracentesis (LVP). It is found that, the combination of albumin with antibiotics is clinically more effective than antibiotics alone in the hepatorenal syndrome treatment landscape. To reduce the severe complications of cirrhosis amongst HRS patients, healthcare companies in the hepatorenal syndrome treatment market are increasing awareness about the combination therapy of albumin with vasoconstrictors.
Albumin is being increasingly used in combination with other drugs such as terlipressin. This trend is gaining increased popularity due to its low medical complication costs. Due to reduced rates of renal impairment and reduced mortality rates, health commissions across various countries are recommending the prescription of albumin to treat serious conditions of HRS.
HRS is characterized by renal failure in patients suffering from advanced chronic liver disease (CLD). This disease condition has led to increased hospitalizations in the U.S. As such, the U.S. currently accounts for the highest revenue amongst all regions in the hepatorenal syndrome treatment market, with a value recorded at ~US$ 5 billion in 2018. Therefore, companies in the hepatorenal syndrome treatment market are increasing their efforts to introduce advanced treatment options for HRS patients in the U.S. However, it is found that, there is a growing need for cost-efficient treatment alternatives for the diagnosis of HRS in the U.S. Costly HRS treatments have created the problem of economic burden amongst patients. This has adversely affected the credibility of outcomes, as patients lack access to cost-efficient and effective treatment options.
Hence, companies in the hepatorenal syndrome treatment market are carrying out extensive research to analyze the number of hospitals that offer treatments at a higher cost. This is particularly compared with hospitals in the developing countries of Asia Pacific. For instance, it has been found that, the cost of treatment for HRS is less expensive in India as compared to the economic evaluation of treatment offered in Brazil. Companies in the hepatorenal syndrome treatment market are increasing research & development to devise strategies that reduce the economic burden on patients, and are increasing the availability of effective treatment options at U.S. hospitals.
Analysts’ Viewpoint
In 2027, surgical treatments are projected to account for ~94% market share of the hepatorenal syndrome treatment market. Hence, healthcare companies should focus on the application of evidence-based algorithms, catering to surgical and pharmacological options for patients suffering from HRS.
However, surgical repair of umbilical hernia in cirrhotic patients has increased risks of high postoperative morbidity and mortality. To overcome this hurdle, companies should aid healthcare providers to increase their efficacy in elective surgery with perioperative preparations to ensure effective and safe outcomes after a surgery. Since HRS treatment is less expensive in Asia Pacific, healthcare companies should capitalize on this opportunity, as the region is estimated for exponential market growth amongst all the other regions in the landscape.
Global Hepatorenal Syndrome Treatment Market: Overview
Global Hepatorenal Syndrome Treatment Market: Significant Growth Prospects in Developing Countries
Increase in Disease Awareness & Patient Support Programs to Boost Hepatorenal Syndrome Treatment Market
Global Hepatorenal Syndrome Treatment Market: Fast Track and Orphan Drug Designations
Global Hepatorenal Syndrome Treatment Market: Competition Landscape
Hepatorenal syndrome treatment market to reach a valuation of ~US$ 16.7 Bn by 2027
Hepatorenal syndrome treatment market is projected to expand at a CAGR of ~5% from 2019 to 2027
Hepatorenal syndrome treatment market is driven by an increase in the awareness and acceptance of hepatorenal syndrome treatment
North America accounted for a major share of the global hepatorenal syndrome treatment market
Key players in the global hepatorenal syndrome treatment market include Cumberland Pharmaceuticals, Inc., Orphan Therapeutics, LLC, BioVie Inc., and Mallinckrodt Pharmaceuticals.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Hepatorenal Syndrome Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Hepatorenal Syndrome Treatment Market: Type Overview
4.2. Global Hepatorenal Syndrome Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Fast track and orphan drug designations
4.5.2. Increase in strategic collaboration among key players
4.6. Restraints
4.6.1. Side-effects and risks related to drug usage
4.6.2. Stringent regulatory requirements
4.7. Opportunities
4.8. Global Hepatorenal Syndrome Treatment Market Revenue Projections (US$ Mn), 2017–2027
5. Key Insights
5.1. Pipeline Analysis
5.2. Regulatory Scenario by Region/Country
5.3. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc)
5.4. Prevalence of Liver & Kidney Diseases by Region/Globally
6. Global Hepatorenal Syndrome Treatment Market Analysis, by Type
6.1. Introduction
6.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
6.2.1. Type 1 Hepatorenal Syndrome
6.2.2. Type 2 Hepatorenal Syndrome
6.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Type
6.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Type
7. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment
7.1. Introduction
7.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
7.2.1. Therapeutics
7.2.1.1. Terlivaz
7.2.1.2. Glypressin
7.2.1.3. Lucassin
7.2.1.4. Hepatoren
7.2.2. Surgical Treatment
7.2.2.1. Liver Transplantation
7.2.2.2. Surgical Shunting
7.2.2.2.1. Peritoneovenous Shunting
7.2.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
7.2.2.2.3. Others
7.2.2.3. Renal Replacement Therapy
7.2.2.4. Others
7.3. Global Hepatorenal Syndrome Treatment Market Analysis, by Treatment
7.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Treatment
8. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user
8.1. Introduction
8.2. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
8.2.1. Hospitals & Clinics
8.2.2. Ambulatory Surgical Centers
8.2.3. Academic & Research Institutes
8.2.4. Others
8.3. Global Hepatorenal Syndrome Treatment Market Analysis, by End-user
8.4. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by End-user
9. Global Hepatorenal Syndrome Treatment Market Analysis, by Region
9.1. Global Hepatorenal Syndrome Treatment Market Value and Forecast, by Region, 2017–2027
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Global Hepatorenal Syndrome Treatment Market Analysis, by Region
9.3. Global Hepatorenal Syndrome Treatment Market Attractiveness Analysis, by Region
10. North America Hepatorenal Syndrome Treatment Market Analysis
10.1. North America Hepatorenal Syndrome Treatment Market
10.2. North America Hepatorenal Syndrome Treatment Market Overview
10.3. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
10.3.1. Type 1 Hepatorenal Syndrome
10.3.2. Type 2 Hepatorenal Syndrome
10.4. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
10.4.1. Therapeutics
10.4.1.1. Terlivaz
10.4.1.2. Glypressin
10.4.1.3. Lucassin
10.4.1.4. Hepatoren
10.4.2. Surgical Treatment
10.4.2.1. Liver Transplantation
10.4.2.2. Surgical Shunting
10.4.2.2.1. Peritoneovenous Shunting
10.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
10.4.2.2.3. Others
10.4.2.3. Renal Replacement Therapy
10.4.3. Others
10.5. North America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
10.5.1. Hospitals & Clinics
10.5.2. Ambulatory Surgical Centers
10.5.3. Academic & Research Institutes
10.5.4. Others
10.6. North America Hepatorenal Syndrome Treatment Market Forecast, by Country
10.6.1. U.S.
10.6.2. Canada
10.7. North America Hepatorenal Syndrome Treatment Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Treatment
10.7.3. By End-user
10.7.4. By Country
11. Europe Hepatorenal Syndrome Treatment Market Analysis
11.1. Europe Hepatorenal Syndrome Treatment Market
11.2. Europe Hepatorenal Syndrome Treatment Market Overview
11.3. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
11.3.1. Type 1 Hepatorenal Syndrome
11.3.2. Type 2 Hepatorenal Syndrome
11.4. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
11.4.1. Therapeutics
11.4.1.1. Terlivaz
11.4.1.2. Glypressin
11.4.1.3. Lucassin
11.4.1.4. Hepatoren
11.4.2. Surgical Treatment
11.4.2.1. Liver Transplantation
11.4.2.2. Surgical Shunting
11.4.2.2.1. Peritoneovenous Shunting
11.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
11.4.2.2.3. Others
11.4.2.3. Renal Replacement Therapy
11.4.3. Others
11.5. Europe Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
11.5.1. Hospitals & Clinics
11.5.2. Ambulatory Surgical Centers
11.5.3. Academic & Research Institutes
11.5.4. Others
11.6. Europe Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
11.6.1. U.K.
11.6.2. France
11.6.3. Germany
11.6.4. Spain
11.6.5. Italy
11.6.6. Rest of Europe
11.7. Europe Hepatorenal Syndrome Treatment Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Treatment
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Hepatorenal Syndrome Treatment Market Analysis
12.1. Asia Pacific Hepatorenal Syndrome Treatment Market Key Findings
12.2. Asia Pacific Hepatorenal Syndrome Treatment Market Overview
12.3. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
12.3.1. Type 1 Hepatorenal Syndrome
12.3.2. Type 2 Hepatorenal Syndrome
12.4. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
12.4.1. Therapeutics
12.4.1.1. Terlivaz
12.4.1.2. Glypressin
12.4.1.3. Lucassin
12.4.1.4. Hepatoren
12.4.2. Surgical Treatment
12.4.2.1. Liver Transplantation
12.4.2.2. Surgical Shunting
12.4.2.2.1. Peritoneovenous Shunting
12.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
12.4.2.2.3. Others
12.4.2.3. Renal Replacement Therapy
12.4.3. Others
12.5. Asia Pacific Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
12.5.1. Hospitals & Clinics
12.5.2. Ambulatory Surgical Centers
12.5.3. Academic & Research Institutes
12.5.4. Others
12.6. Asia Pacific Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
12.6.1. China
12.6.2. India
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Treatment
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Hepatorenal Syndrome Treatment Market Analysis
13.1. Latin America Hepatorenal Syndrome Treatment Market Key Findings
13.2. Latin America Hepatorenal Syndrome Treatment Market Overview
13.3. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
13.3.1. Type 1 Hepatorenal Syndrome
13.3.2. Type 2 Hepatorenal Syndrome
13.4. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
13.4.1. Therapeutics
13.4.1.1. Terlivaz
13.4.1.2. Glypressin
13.4.1.3. Lucassin
13.4.1.4. Hepatoren
13.4.2. Surgical Treatment
13.4.2.1. Liver Transplantation
13.4.2.2. Surgical Shunting
13.4.2.2.1. Peritoneovenous Shunting
13.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
13.4.2.2.3. Others
13.4.2.3. Renal Replacement Therapy
13.4.3. Others
13.5. Latin America Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
13.5.1. Hospitals & Clinics
13.5.2. Ambulatory Surgical Centers
13.5.3. Academic & Research Institutes
13.5.4. Others
13.6. Latin America Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Latin America Hepatorenal Syndrome Treatment Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Treatment
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Hepatorenal Syndrome Treatment Market Analysis
14.1. Middle East & Africa Hepatorenal Syndrome Treatment Market
14.2. Middle East & Africa Hepatorenal Syndrome Treatment Market Overview
14.3. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Type
14.3.1. Type 1 Hepatorenal Syndrome
14.3.2. Type 2 Hepatorenal Syndrome
14.4. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by Treatment
14.4.1. Therapeutics
14.4.1.1. Terlivaz
14.4.1.2. Glypressin
14.4.1.3. Lucassin
14.4.1.4. Hepatoren
14.4.2. Surgical Treatment
14.4.2.1. Liver Transplantation
14.4.2.2. Surgical Shunting
14.4.2.2.1. Peritoneovenous Shunting
14.4.2.2.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
14.4.2.2.3. Others
14.4.2.3. Renal Replacement Therapy
14.4.3. Others
14.5. Middle East & Africa Hepatorenal Syndrome Treatment Market Value and Forecast, by End-user
14.5.1. Hospitals & Clinics
14.5.2. Ambulatory Surgical Centers
14.5.3. Academic & Research Institutes
14.5.4. Others
14.6. Middle East & Africa Hepatorenal Syndrome Treatment Market Forecast, by Country/Sub-region
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Treatment
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competitive Landscape
15.1. Company Profiles
15.1.1. Cumberland Pharmaceuticals, Inc.
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Orphan Therapeutics, LLC.
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. BioVie Inc.
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. Mallinckrodt Pharmaceuticals
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
List of Tables
TABLE 1 Global Hepatorenal Syndrome Treatment Pipeline Analysis (1/5)
TABLE 2 Global Hepatorenal Syndrome Treatment Pipeline Analysis (2/5)
TABLE 3 Global Hepatorenal Syndrome Treatment Pipeline Analysis (3/5)
TABLE 4 Global Hepatorenal Syndrome Treatment Pipeline Analysis (4/5)
TABLE 5 Global Hepatorenal Syndrome Treatment Pipeline Analysis (5/5)
TABLE 6 Comparative Analysis of Orphan Drug Policies
TABLE 7 Worldwide Epidemiology of Liver Diseases
TABLE 8 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 9 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 10 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 11 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 12 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 13 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 14 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
TABLE 15 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
TABLE 16 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 17 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 18 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 19 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 20 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 21 North America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 22 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 23 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 24 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 25 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 26 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 27 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 28 Europe Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 29 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 30 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 31 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 32 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 33 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 34 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 35 Asia Pacific Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 36 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 37 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 38 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 39 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 40 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 41 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 42 Latin America Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
TABLE 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 46 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2027
TABLE 47 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Treatment, 2017–2027
TABLE 48 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by Surgical Shunting, 2017–2027
TABLE 49 Middle East & Africa Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
List of Figures
FIG. 1 Global Hepatorenal Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 2 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type (2018)
FIG. 3 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment (2018)
FIG. 4 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user (2018)
FIG. 5 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region (2018)
FIG. 6 Regulatory Approval Process - U.S.
FIG. 7 Regulatory Approval Process - Europe
FIG. 8 Regulatory Approval Process - Japan
FIG. 9 Regulatory Approval Process - China
FIG. 10 Revision of Drug Administration Law & Drug Registration Regulation
FIG. 11 Drug Approval Process in China - Step 1
FIG. 12 Drug Approval Process in China - Step 2
FIG. 13 Drug Approval Process in China - Step 3
FIG. 14 Recent CFDA Regulatory Reforms to Support Innovative Drugs
FIG. 15 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Type, 2018 and 2027
FIG. 16 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Type, 2019–2027
FIG. 17 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 1 Hepatorenal Syndrome, 2017–2027
FIG. 18 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Type 2 Hepatorenal Syndrome, 2017–2027
FIG. 19 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Treatment, 2018 and 2027
FIG. 20 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 21 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Therapeutics, 2017–2027
FIG. 22 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Surgical Treatment, 2017–2027
FIG. 23 Global Hepatorenal Syndrome Treatment Market Value Share (%), by End-user, 2018 and 2027
FIG. 24 Global Hepatorenal Syndrome Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 25 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals & Clinics, 2017–2027
FIG. 26 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027
FIG. 27 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Academic & Research Institutes, 2017–2027
FIG. 28 Global Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
FIG. 29 Global Hepatorenal Syndrome Treatment Market Value Share (%), by Region, 2018 and 2027
FIG. 30 Global Hepatorenal Syndrome Treatment Market Attractiveness, by Region, 2019–2027
FIG. 31 North America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
FIG. 32 North America Hepatorenal Syndrome Treatment Market Value Share (%), by Country, 2018 and 2027
FIG. 33 North America Hepatorenal Syndrome Treatment Market Attractiveness, by Country, 2019–2027
FIG. 34 Europe Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
FIG. 35 Europe Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
FIG. 36 Europe Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 37 Asia Pacific Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
FIG. 38 Asia Pacific Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
FIG. 39 Asia Pacific Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 40 Latin America Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
FIG. 41 Latin America Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
FIG. 42 Latin America Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 43 Middle East & Africa Hepatorenal Syndrome Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
FIG. 44 Middle East & Africa Hepatorenal Syndrome Treatment Market Value Share (%), by Country/Sub-region, 2018 and 2027
FIG. 45 Middle East & Africa Hepatorenal Syndrome Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 46 Cumberland Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018
FIG. 47 Cumberland Pharmaceuticals, Inc., Breakdown of Net Sales, by Region, 2018
FIG. 48 Mallinckrodt Pharmaceuticals, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
FIG. 49 Mallinckrodt Pharmaceuticals, R&D Expenses, 2015–2018
FIG. 50 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Region, 2018
FIG. 51 Mallinckrodt Pharmaceuticals, Breakdown of Net Sales, by Business Segment, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hepatorenal Syndrome Treatment Market
